Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03927040 · ClinicalTrials.gov registry record · NA
Transcranial Electromagnetic Treatment Against Alzheimer's Disease
A NA study, sponsored by NeuroEM Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT03927040: Completed NA study, sponsored by NeuroEM Therapeutics.
NCT03927040 is a NA study that has completed, run by NeuroEM Therapeutics. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03927040, a NA study, has completed, sponsored by NeuroEM Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an extension of EM 1000-1 wherein subjects who participated in the original study have been given the opportunity to participate in a 4-month extension of TEMT. Seven of the eight subjects in the original EM 1000-1 agreed to participate in this study extension. The time between completion of the initial study's 2-month treatment period and the beginning of this extension study's 4-month treatment period will range from 4 months to 13 months (due to staggered start of treatment in the initial study). This extension study's primary objective is to determine the effects of a follow-up treatment period of 4-months on performance of Alzheimer's Disease (AD) subjects in the same comprehensive array of cognitive tasks they performed in the initial 2-month treatment study. Baseline cognitive performance will be compared to performance at both 2-months into treatment and at the end of the 4-month treatment period. Secondary objectives include analysis of blood and CSF for AD markers and evaluation of safety throughout the treatment period.
Primary Outcome
ADAS-cog is the standard/benchmark test of cognitive performance evaluated in Alzheimer's treatment-based clinical trials.
Interventions
- DEVICE MemorEM 1000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2020-10-30 |
| Phase | NA |
What the finished NCT03927040 record still lists
NCT03927040 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which MemorEM 1000 is the first listed.
NCT03927040 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03927040 about?
NCT03927040 is a clinical study titled "Transcranial Electromagnetic Treatment Against Alzheimer's Disease". This is an extension of EM 1000-1 wherein subjects who participated in the original study have been given the opportunity to participate in a 4-month extension of TEMT. Seven of the eight subjects in the original EM 1000-1 agreed to participate in this study extension. The time between completion of...
What is the current status of trial NCT03927040?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2019-04-15. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT03927040?
The interventions under investigation include: MemorEM 1000 (DEVICE).
Who is sponsoring clinical trial NCT03927040?
This trial is sponsored by NeuroEM Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03927040's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI